Neurological complications of immune checkpoint inhibitors: what happens when you ‘take the brakes off’ the immune system

• Published in: Therapeutic advances in neurological disorders Vol. 11; p. 1756286418799864
• Main Author: Dalakas, Marinos C.
• Format: Journal Article
• Language: English
• Published: London, England SAGE Publications 01.01.2018; SAGE PUBLICATIONS, INC; SAGE Publishing
• Subjects: Immune checkpoint inhibitors; Immunological diseases; Immunotherapy; Neuropathy; Review; neuro-immunology; immune-related neurological complications; immune checkpoint inhibitors; autoimmune neurological disorders; immunotherapy; neurological side effects
• ISSN: 1756-2864; 1756-2856; 1756-2864
• DOI: 10.1177/1756286418799864

Patients with advanced malignancies treated with immune checkpoint inhibitors are at increased risk for developing immune-related neurological complications. It is a phenomenon of immunological twist when immunotherapy against co-stimulatory molecules activates previously normal T cells to kill tumor cells but, in so doing, the T cells become unrestrained, triggering other autoimmune diseases for which conventional immunotherapy is needed. The most common autoimmune neurological diseases, usually occurring within 2–12 weeks after immune checkpoint inhibitor initiation, include: inflammatory myopathies, myasthenia gravis, acute and chronic demyelinating polyradiculoneuropathies, vasculitic neuropathies, isolated cranial neuropathies, aseptic meningitis, autoimmune encephalitis, multiple sclerosis and hypophysitis. The neurological events can evolve rapidly, necessitating the need for vigilance at all stages of treatment, even after completion, because early immunotherapeutic interventions are effective. The review addresses these complications and the applied therapies, discusses immune pathomechanisms including triggering preexisting autoimmunity, highlights the distinction between paraneoplastic and autoimmune etiologies, and identifies uncertainties regarding risk factors, use of immune checkpoint inhibitors in patients with known immune diseases or restarting therapy after a neurological event. Although the autoimmune neurological complications are not very common, their incidence will likely increase as the use of immune checkpoint inhibitors in metastatic cancer is growing rapidly.